{
  "docId": "019de076-4a3e-76ed-83f8-e348223f91d9",
  "docSlug": "c1eecdcf261eded4e99ffa840c30e475",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 33,
  "pageCount": 60,
  "prevPage": 32,
  "nextPage": 34,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "The slide uses a side-by-side comparison of two disease indications, each with its own clinical data points and relevant market benchmarks.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/33",
  "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9",
  "deckJsonHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9.json",
  "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-33",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.96,
        "x": 0.02,
        "y": 0.93
      },
      "kind": "disclaimer",
      "text": "Source: BMS First Quarter 2022 financial results...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e2bd9861-2108-425d-991d-2e0f8829282b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.1,
        "x": 0.87,
        "y": 0.03
      },
      "kind": "image",
      "text": "Immix Biopharma",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "148c9cdd-5447-45b6-951d-a05dc78f8ea5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.96,
        "x": 0.02,
        "y": 0.65
      },
      "kind": "image",
      "text": "Competitor logos and products",
      "attrs": null,
      "subkind": "logo-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9b6868ea-5203-4f38-8cc3-1ae56073a43d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.96,
        "x": 0.02,
        "y": 0.15
      },
      "kind": "list",
      "text": "Clinical highlights for Multiple Myeloma and AL Amyloidosis",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ab81caf8-7aa1-4e40-b01e-451342283f81",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.48,
        "x": 0.02,
        "y": 0.85
      },
      "kind": "metric",
      "text": "176,404 patient annual incidence",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "61d8b2c7-bad1-485a-850b-13f741d3ffb6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.48,
        "x": 0.52,
        "y": 0.85
      },
      "kind": "metric",
      "text": "14,982 patient annual incidence",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d59aab6-4bec-456d-ac46-5bce75130ab9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.65,
        "x": 0.02,
        "y": 0.03
      },
      "kind": "title",
      "text": "NXC-201 Clinical Highlights: 4% Neurotoxicity Across 50 Patients; Outpatient CAR-T Potential",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8a4ceaa7-42c0-4f3f-8058-df5d19096d6f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "f794fc4c-6207-4e59-a205-020eedd6d75e",
      "evidence": "Side-by-side clinical data presentation for two distinct indications",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 34,
      "from": 18,
      "beatId": "59dea3e4-911d-4dc4-b5bf-44d94b3ffdaf",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "Slides 18-34: Various traction slides",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 60,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "50c25ad2-0c48-4213-947d-b362da490be1",
      "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative",
      "position": 1,
      "objective": "Why is Immix Biopharma's N-GENIUS platform important?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}